Current Environment: Production

Warning

Recall Alert

There is an antibacterial antibiotic recall. Read more

617-355-7800

Department of Surgery | Education

Undergraduate School

Bryn Mawr College

1999, Bryn Mawr, PA

Medical School

Harvard Medical School

2007, Boston, MA

Internship

Brigham and Women's Hospital

2008, Boston, MA

Residency

Brigham and Women's Hospital

2015, Boston, MA

Fellowship

Brigham and Women's Hospital

2016, Boston, MA

Department of Surgery | Education

Undergraduate School

University of California at Berkley

1987, Berkley, CA

Medical School

University of Vermont

1992, Burlington, VT

Residency

Rhode Island Hospital, Brown University

Providence, RI

Fellowship

Tufts New England Floating Hospital for Children

Boston, MA

Fellowship

Boston Children's Hospital

Boston, MA

Department of Surgery | Publications

  1. Optimizing Efficacy of Vacuum Bell Therapy for Pectus Excavatum: Compliance is Key. J Surg Res. 2025 Apr; 308:112-121. View Optimizing Efficacy of Vacuum Bell Therapy for Pectus Excavatum: Compliance is Key. Abstract

  2. Ustekinumab-Induced Vasculitis in a Patient With Crohn's Disease. ACG Case Rep J. 2025 Mar; 12(3):e01625. View Ustekinumab-Induced Vasculitis in a Patient With Crohn's Disease. Abstract

  3. The CNS microenvironment promotes leukemia cell survival by disrupting tumor suppression and cell cycle regulation in pediatric T-cell acute lymphoblastic leukemia. Exp Cell Res. 2024 Apr 15; 437(2):114015. View The CNS microenvironment promotes leukemia cell survival by disrupting tumor suppression and cell cycle regulation in pediatric T-cell acute lymphoblastic leukemia. Abstract

  4. Latiglutenase Protects the Mucosa and Attenuates Symptom Severity in Patients With Celiac Disease Exposed to a Gluten Challenge. Gastroenterology. 2022 12; 163(6):1510-1521.e6. View Latiglutenase Protects the Mucosa and Attenuates Symptom Severity in Patients With Celiac Disease Exposed to a Gluten Challenge. Abstract

  5. Electron Signatures of Reconnection in a Global eVlasiator Simulation. Geophys Res Lett. 2022 Jul 28; 49(14):e2022GL098329. View Electron Signatures of Reconnection in a Global eVlasiator Simulation. Abstract

  6. Quasi-Parallel Shock Reformation Seen by Magnetospheric Multiscale and Ion-Kinetic Simulations. Geophys Res Lett. 2022 Jan 28; 49(2):e2021GL096335. View Quasi-Parallel Shock Reformation Seen by Magnetospheric Multiscale and Ion-Kinetic Simulations. Abstract

  7. Vulvar Crohn's Disease: Clinical Features and Outcomes. Am J Gastroenterol. 2021 11 01; 116(11):2296-2299. View Vulvar Crohn's Disease: Clinical Features and Outcomes. Abstract

  8. Certolizumab Trough Levels and Antibodies in Crohn Disease: A Single-Center Experience. Crohns Colitis 360. 2021 Jul; 3(3):otab019. View Certolizumab Trough Levels and Antibodies in Crohn Disease: A Single-Center Experience. Abstract

  9. A 1-Year Cross-sectional Inflammatory Bowel Disease Surveillance Colonoscopy Cohort Comparing High-definition White Light Endoscopy and Chromoendoscopy. Inflamm Bowel Dis. 2021 04 15; 27(5):594-602. View A 1-Year Cross-sectional Inflammatory Bowel Disease Surveillance Colonoscopy Cohort Comparing High-definition White Light Endoscopy and Chromoendoscopy. Abstract

  10. Parasitic omental endometrioma: an unexpected iatrogenic sequalae of morcellation in disseminating de novo benign peritoneal disease. J Obstet Gynaecol. 2021 Jan; 41(1):167-168. View Parasitic omental endometrioma: an unexpected iatrogenic sequalae of morcellation in disseminating de novo benign peritoneal disease. Abstract

  11. Perineal integrity can be guarded by polishing our intrapartum skills. Aust N Z J Obstet Gynaecol. 2020 06; 60(3):E6. View Perineal integrity can be guarded by polishing our intrapartum skills. Abstract

  12. Combination Biologic Therapy in Inflammatory Bowel Disease: Experience From a Tertiary Care Center. Clin Gastroenterol Hepatol. 2021 03; 19(3):616-617. View Combination Biologic Therapy in Inflammatory Bowel Disease: Experience From a Tertiary Care Center. Abstract

  13. Intravenous Bevacizumab Reduces Transfusion Requirements and Endoscopic Interventions in Patients With Gastric Antral Vascular Ectasia and Small Bowel Angioectasia. Gastroenterology. 2020 03; 158(4):1162-1163.e4. View Intravenous Bevacizumab Reduces Transfusion Requirements and Endoscopic Interventions in Patients With Gastric Antral Vascular Ectasia and Small Bowel Angioectasia. Abstract

  14. The Combination of Patient-Reported Clinical Symptoms and an Endoscopic Score Correlates Well with Health-Related Quality of Life in Patients with Ulcerative Colitis. J Clin Med. 2019 Aug 05; 8(8). View The Combination of Patient-Reported Clinical Symptoms and an Endoscopic Score Correlates Well with Health-Related Quality of Life in Patients with Ulcerative Colitis. Abstract

  15. Evaluating the value of intrapartum fetal scalp blood sampling to predict adverse neonatal outcomes: A UK multicentre observational study. Eur J Obstet Gynecol Reprod Biol. 2019 Sep; 240:62-67. View Evaluating the value of intrapartum fetal scalp blood sampling to predict adverse neonatal outcomes: A UK multicentre observational study. Abstract

  16. Vedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019 02 21; 25(3):580-586. View Vedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease. Abstract

  17. Narrow band imaging evaluation of duodenal villi in patients with and without celiac disease: A prospective study. World J Gastrointest Endosc. 2019 Feb 16; 11(2):145-154. View Narrow band imaging evaluation of duodenal villi in patients with and without celiac disease: A prospective study. Abstract

  18. Mechanisms of Disease: Inflammatory Bowel Diseases. Mayo Clin Proc. 2019 01; 94(1):155-165. View Mechanisms of Disease: Inflammatory Bowel Diseases. Abstract

  19. Outcomes of Treatment for Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy. Inflamm Bowel Dis. 2018 09 15; 24(10):2272-2277. View Outcomes of Treatment for Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy. Abstract

  20. Phenotype and Clinical Course of Inflammatory Bowel Disease With Co-existent Celiac Disease. J Crohns Colitis. 2018 Jul 30; 12(8):973-980. View Phenotype and Clinical Course of Inflammatory Bowel Disease With Co-existent Celiac Disease. Abstract

  21. Clinical Benefit of Capsule Endoscopy in Crohn's Disease: Impact on Patient Management and Prevalence of Proximal Small Bowel Involvement. Inflamm Bowel Dis. 2018 06 08; 24(7):1582-1588. View Clinical Benefit of Capsule Endoscopy in Crohn's Disease: Impact on Patient Management and Prevalence of Proximal Small Bowel Involvement. Abstract

  22. Concurrent Sweet's syndrome and myopericarditis following mesalamine therapy. BMJ Case Rep. 2018 Mar 23; 2018. View Concurrent Sweet's syndrome and myopericarditis following mesalamine therapy. Abstract

  23. Targeting Specific Immunologic Pathways in Crohn's Disease. Gastroenterol Clin North Am. 2017 09; 46(3):577-588. View Targeting Specific Immunologic Pathways in Crohn's Disease. Abstract

  24. Inflammatory Bowel Disease: Updates on Molecular Targets for Biologics. Gut Liver. 2017 Jul 15; 11(4):455-463. View Inflammatory Bowel Disease: Updates on Molecular Targets for Biologics. Abstract

  25. Aberrant function of myeloid-derived suppressor cells (MDSCs) in experimental colitis and in inflammatory bowel disease (IBD) immune responses. Autoimmunity. 2017 May; 50(3):170-181. View Aberrant function of myeloid-derived suppressor cells (MDSCs) in experimental colitis and in inflammatory bowel disease (IBD) immune responses. Abstract

  26. P616 Natural history and phenotype of inflammatory bowel disease with co-existent celiac disease. J Crohns Colitis. 2017 Feb 01; 11(suppl_1):S394-S395. View P616 Natural history and phenotype of inflammatory bowel disease with co-existent celiac disease. Abstract

  27. The Role of the Histone Methyltransferase Enhancer of Zeste Homolog 2 (EZH2) in the Pathobiological Mechanisms Underlying Inflammatory Bowel Disease (IBD). J Biol Chem. 2017 Jan 13; 292(2):706-722. View The Role of the Histone Methyltransferase Enhancer of Zeste Homolog 2 (EZH2) in the Pathobiological Mechanisms Underlying Inflammatory Bowel Disease (IBD). Abstract

  28. O-015 YI Alterations in the FOXP3-EZH2 Pathway Associates with Increased Susceptibility to Colitis in Both Mice and Human. Inflamm Bowel Dis. 2016 Mar; 22 Suppl 1:S5-6. View O-015 YI Alterations in the FOXP3-EZH2 Pathway Associates with Increased Susceptibility to Colitis in Both Mice and Human. Abstract

  29. A case report of sevelamer-associated recto-sigmoid ulcers. BMC Gastroenterol. 2016 Feb 24; 16:20. View A case report of sevelamer-associated recto-sigmoid ulcers. Abstract

  30. Krüppel-like factor KLF10 deficiency predisposes to colitis through colonic macrophage dysregulation. Am J Physiol Gastrointest Liver Physiol. 2015 Dec 01; 309(11):G900-9. View Krüppel-like factor KLF10 deficiency predisposes to colitis through colonic macrophage dysregulation. Abstract

  31. Apolipoprotein A-I inhibits experimental colitis and colitis-propelled carcinogenesis. Oncogene. 2016 05 12; 35(19):2496-505. View Apolipoprotein A-I inhibits experimental colitis and colitis-propelled carcinogenesis. Abstract

  32. Ipilimumab-induced colitis in patients with metastatic melanoma. Melanoma Res. 2015 Aug; 25(4):321-7. View Ipilimumab-induced colitis in patients with metastatic melanoma. Abstract

  33. New-onset paresthesias in inflammatory bowel disease. Gastroenterology. 2015 May; 148(5):906-7. View New-onset paresthesias in inflammatory bowel disease. Abstract

  34. An uncommon cause of abdominal pain and fever in a patient with Crohn's disease. Gastroenterology. 2015 May; 148(5):e12-3. View An uncommon cause of abdominal pain and fever in a patient with Crohn's disease. Abstract

  35. A novel role for KLF14 in T regulatory cell differentiation. Cell Mol Gastroenterol Hepatol. 2015 Mar 01; 1(2):188-202.e4. View A novel role for KLF14 in T regulatory cell differentiation. Abstract

  36. Predictors of health-related quality of life and adherence in Crohn's disease and ulcerative colitis: implications for clinical management. Dig Dis Sci. 2015 May; 60(5):1366-74. View Predictors of health-related quality of life and adherence in Crohn's disease and ulcerative colitis: implications for clinical management. Abstract

  37. Krüppel-like factor KLF10 regulates transforming growth factor receptor II expression and TGF-ß signaling in CD8+ T lymphocytes. Am J Physiol Cell Physiol. 2015 Mar 01; 308(5):C362-71. View Krüppel-like factor KLF10 regulates transforming growth factor receptor II expression and TGF-ß signaling in CD8+ T lymphocytes. Abstract

  38. Pharmacogenetics of inflammatory bowel disease. Pharmacogenomics. 2014 Dec; 15(16):2049-62. View Pharmacogenetics of inflammatory bowel disease. Abstract

  39. Immunology of inflammatory bowel disease and molecular targets for biologics. Gastroenterol Clin North Am. 2014 Sep; 43(3):405-24. View Immunology of inflammatory bowel disease and molecular targets for biologics. Abstract

  40. Lymphocyte homing antagonists in the treatment of inflammatory bowel diseases. Gastroenterol Clin North Am. 2014 Sep; 43(3):581-601. View Lymphocyte homing antagonists in the treatment of inflammatory bowel diseases. Abstract

  41. Prolonged idiopathic gastric dilatation following revascularization for chronic mesenteric ischemia. Ann Gastroenterol. 2014; 27(3):273-275. View Prolonged idiopathic gastric dilatation following revascularization for chronic mesenteric ischemia. Abstract

  42. Cytomegalovirus infection of the ileoanal pouch: clinical characteristics and outcomes. Inflamm Bowel Dis. 2013 Oct; 19(11):2394-9. View Cytomegalovirus infection of the ileoanal pouch: clinical characteristics and outcomes. Abstract

  43. Chronic diarrhea after autologous stem cell transplantation for peripheral T-cell lymphoma. Gastroenterology. 2013 Aug; 145(2):e3-5. View Chronic diarrhea after autologous stem cell transplantation for peripheral T-cell lymphoma. Abstract

  44. Hepcidin is a key mediator of anemia of inflammation in Crohn's disease. J Crohns Colitis. 2013 Sep; 7(8):e286-91. View Hepcidin is a key mediator of anemia of inflammation in Crohn's disease. Abstract

  45. Treatment of experimental murine colitis with CD40 antisense oligonucleotides delivered in amphoteric liposomes. J Control Release. 2013 Feb 10; 165(3):163-72. View Treatment of experimental murine colitis with CD40 antisense oligonucleotides delivered in amphoteric liposomes. Abstract

  46. Colorectal cancer screening and surveillance in Crohn's colitis. J Crohns Colitis. 2012 Sep; 6(8):824-9. View Colorectal cancer screening and surveillance in Crohn's colitis. Abstract

  47. Predicting outcomes after restorative proctocolectomy for ulcerative colitis. Clin Gastroenterol Hepatol. 2012 May; 10(5):447-9. View Predicting outcomes after restorative proctocolectomy for ulcerative colitis. Abstract

  48. Dysplasia and cancer in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2011 Feb; 5(1):59-66. View Dysplasia and cancer in inflammatory bowel disease. Abstract

  49. Pulmonary manifestations of inflammatory bowel disease: case presentations and review. J Crohns Colitis. 2010 Oct; 4(4):390-7. View Pulmonary manifestations of inflammatory bowel disease: case presentations and review. Abstract

  50. Combination of innate and adaptive immune alterations increased the likelihood of fibrostenosis in Crohn's disease. Inflamm Bowel Dis. 2010 Aug; 16(8):1279-85. View Combination of innate and adaptive immune alterations increased the likelihood of fibrostenosis in Crohn's disease. Abstract

  51. A case of orbital myositis preceding the intestinal symptoms of Crohn's disease. J Crohns Colitis. 2010 Sep; 4(3):349-50. View A case of orbital myositis preceding the intestinal symptoms of Crohn's disease. Abstract

  52. Report of the ECCO workshop on anti-TNF therapy failures in inflammatory bowel diseases: biological roles and effects of TNF and TNF antagonists. J Crohns Colitis. 2010 Oct; 4(4):367-76. View Report of the ECCO workshop on anti-TNF therapy failures in inflammatory bowel diseases: biological roles and effects of TNF and TNF antagonists. Abstract

  53. CD8+ cells protect mice against reinfection with the intestinal parasite Eimeria falciformis. Microbes Infect. 2010 Mar; 12(3):218-26. View CD8+ cells protect mice against reinfection with the intestinal parasite Eimeria falciformis. Abstract

  54. Diagnostic approach to small bowel involvement in inflammatory bowel disease: view of the endoscopist. Dig Dis. 2009; 27(4):476-81. View Diagnostic approach to small bowel involvement in inflammatory bowel disease: view of the endoscopist. Abstract

  55. Capsule endoscopy in patients with Crohn's disease: diagnostic yield and safety. Gastrointest Endosc. 2010 Jan; 71(1):121-7. View Capsule endoscopy in patients with Crohn's disease: diagnostic yield and safety. Abstract

  56. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am J Gastroenterol. 2010 Jan; 105(1):148-54. View Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Abstract

  57. Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet. 2009 Jun; 41(6):666-76. View Genome-wide association study identifies eight loci associated with blood pressure. Abstract

  58. Musculoskeletal manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2009 Dec; 15(12):1915-24. View Musculoskeletal manifestations of inflammatory bowel disease. Abstract

  59. Crohn's disease: Adalimumab improves quality of life. Nat Rev Gastroenterol Hepatol. 2009 Apr; 6(4):200-1. View Crohn's disease: Adalimumab improves quality of life. Abstract

  60. Comparison of commercially available serologic kits for the detection of celiac disease. J Clin Gastroenterol. 2009 Mar; 43(3):225-32. View Comparison of commercially available serologic kits for the detection of celiac disease. Abstract

  61. Capsule endoscopy in the evaluation and management of inflammatory bowel disease: a future perspective. Expert Rev Mol Diagn. 2009 Jan; 9(1):31-6. View Capsule endoscopy in the evaluation and management of inflammatory bowel disease: a future perspective. Abstract

  62. Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet. 2009 Jan; 41(1):25-34. View Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Abstract

  63. Why are cytokines targeted for biological therapy in IBD? Inflamm Bowel Dis. 2008 Oct; 14 Suppl 2:S121-2. View Why are cytokines targeted for biological therapy in IBD? Abstract

  64. Endoscopic evaluation of patients with inflammatory bowel disease. Inflamm Bowel Dis. 2008 Sep; 14(9):1287-97. View Endoscopic evaluation of patients with inflammatory bowel disease. Abstract

  65. Proximal small intestinal CD detected by CE. Gastrointest Endosc. 2008 Jul; 68(1):202-3; author reply 203-4. View Proximal small intestinal CD detected by CE. Abstract

  66. Visilizumab induces apoptosis of mucosal T lymphocytes in ulcerative colitis through activation of caspase 3 and 8 dependent pathways. Clin Immunol. 2008 Jun; 127(3):322-9. View Visilizumab induces apoptosis of mucosal T lymphocytes in ulcerative colitis through activation of caspase 3 and 8 dependent pathways. Abstract

  67. Common variants near MC4R are associated with fat mass, weight and risk of obesity. Nat Genet. 2008 Jun; 40(6):768-75. View Common variants near MC4R are associated with fat mass, weight and risk of obesity. Abstract

  68. Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients influence pouchitis development after ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol. 2008 May; 6(5):561-8. View Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients influence pouchitis development after ileal pouch-anal anastomosis. Abstract

  69. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease. Dig Liver Dis. 2008 Jun; 40(6):425-32. View Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease. Abstract

  70. LDL-cholesterol concentrations: a genome-wide association study. Lancet. 2008 Feb 09; 371(9611):483-91. View LDL-cholesterol concentrations: a genome-wide association study. Abstract

  71. Minimally invasive closure of pediatric umbilical hernias. J Pediatr Surg. 2008 Jan; 43(1):127-30. View Minimally invasive closure of pediatric umbilical hernias. Abstract

  72. Family history and serology predict Crohn's disease after ileal pouch-anal anastomosis for ulcerative colitis. Dis Colon Rectum. 2008 Jan; 51(1):100-8. View Family history and serology predict Crohn's disease after ileal pouch-anal anastomosis for ulcerative colitis. Abstract

  73. Diagnostic yield of capsule endoscopy in ulcerative colitis and inflammatory bowel disease of unclassified type (IBDU). Endoscopy. 2008 Jan; 40(1):30-5. View Diagnostic yield of capsule endoscopy in ulcerative colitis and inflammatory bowel disease of unclassified type (IBDU). Abstract

  74. Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis? Dis Colon Rectum. 2007 Nov; 50(11):1747-53. View Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis? Abstract

  75. Characterization of FOXP3+CD4+ regulatory T cells in Crohn's disease. Clin Immunol. 2007 Dec; 125(3):281-90. View Characterization of FOXP3+CD4+ regulatory T cells in Crohn's disease. Abstract

  76. Hepatotoxicity of 6-mercaptopurine (6-MP) and Azathioprine (AZA) in adult IBD patients. Am J Gastroenterol. 2007 Nov; 102(11):2488-94. View Hepatotoxicity of 6-mercaptopurine (6-MP) and Azathioprine (AZA) in adult IBD patients. Abstract

  77. A prospective multivariate analysis of clinical factors associated with pouchitis after ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol. 2007 Aug; 5(8):952-8; quiz 887. View A prospective multivariate analysis of clinical factors associated with pouchitis after ileal pouch-anal anastomosis. Abstract

  78. Predicting a change in diagnosis from ulcerative colitis to Crohn's disease: a nested, case-control study. Clin Gastroenterol Hepatol. 2007 May; 5(5):602-8; quiz 525. View Predicting a change in diagnosis from ulcerative colitis to Crohn's disease: a nested, case-control study. Abstract

  79. Esophageal Crohn's disease treated successfully with adalimumab. Inflamm Bowel Dis. 2007 May; 13(5):639-40. View Esophageal Crohn's disease treated successfully with adalimumab. Abstract

  80. Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations. Inflamm Bowel Dis. 2007 May; 13(5):524-30. View Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations. Abstract

  81. Phenotype and effector function of CC chemokine receptor 9-expressing lymphocytes in small intestinal Crohn's disease. J Immunol. 2007 Mar 01; 178(5):3293-300. View Phenotype and effector function of CC chemokine receptor 9-expressing lymphocytes in small intestinal Crohn's disease. Abstract

  82. Expression and functional characterization of FOXP3+ CD4+ regulatory T cells in ulcerative colitis. Inflamm Bowel Dis. 2007 Feb; 13(2):191-9. View Expression and functional characterization of FOXP3+ CD4+ regulatory T cells in ulcerative colitis. Abstract

  83. Antibodies to I2 predict clinical response to fecal diversion in Crohn's disease. Inflamm Bowel Dis. 2006 Dec; 12(12):1122-30. View Antibodies to I2 predict clinical response to fecal diversion in Crohn's disease. Abstract

  84. NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives. Gastroenterology. 2007 Feb; 132(2):576-86. View NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives. Abstract

  85. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol. 2006 Aug; 101(8):1834-40. View Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Abstract

  86. Familial expression of anti-Escherichia coli outer membrane porin C in relatives of patients with Crohn's disease. Gastroenterology. 2006 Apr; 130(4):1078-85. View Familial expression of anti-Escherichia coli outer membrane porin C in relatives of patients with Crohn's disease. Abstract

  87. Adalimumab for the treatment of Crohn's disease. Expert Rev Clin Immunol. 2006 Jan; 2(1):11-5. View Adalimumab for the treatment of Crohn's disease. Abstract

  88. Wireless capsule endoscopy in the evaluation of patients with suspected or known Crohn's disease. Endoscopy. 2005 Oct; 37(10):1018-22. View Wireless capsule endoscopy in the evaluation of patients with suspected or known Crohn's disease. Abstract

  89. Elevated platelet count before ileal pouch-anal anastomosis for ulcerative colitis is associated with the development of chronic pouchitis. Am Surg. 2005 Oct; 71(10):821-6. View Elevated platelet count before ileal pouch-anal anastomosis for ulcerative colitis is associated with the development of chronic pouchitis. Abstract

  90. Serologic responses in indeterminate colitis patients before ileal pouch-anal anastomosis may determine those at risk for continuous pouch inflammation. Dis Colon Rectum. 2005 Jun; 48(6):1254-62. View Serologic responses in indeterminate colitis patients before ileal pouch-anal anastomosis may determine those at risk for continuous pouch inflammation. Abstract

  91. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology. 2005 Jun; 128(7):2020-8. View Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Abstract

  92. Dominant role for TL1A/DR3 pathway in IL-12 plus IL-18-induced IFN-gamma production by peripheral blood and mucosal CCR9+ T lymphocytes. J Immunol. 2005 Apr 15; 174(8):4985-90. View Dominant role for TL1A/DR3 pathway in IL-12 plus IL-18-induced IFN-gamma production by peripheral blood and mucosal CCR9+ T lymphocytes. Abstract

  93. Association of anti-tumor necrosis factor therapy with the development of multiple sclerosis. J Clin Gastroenterol. 2005 Apr; 39(4):303-6. View Association of anti-tumor necrosis factor therapy with the development of multiple sclerosis. Abstract

  94. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol. 2005 Jan; 100(1):75-9. View Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Abstract

  95. Expression and regulation of the chemokine receptor CXCR3 on lymphocytes from normal and inflammatory bowel disease mucosa. Inflamm Bowel Dis. 2004 Nov; 10(6):778-88. View Expression and regulation of the chemokine receptor CXCR3 on lymphocytes from normal and inflammatory bowel disease mucosa. Abstract

  96. Crohn's ileitis after liver transplantation from a living related donor with Crohn's disease. Gut. 2004 Sep; 53(9):1389-90. View Crohn's ileitis after liver transplantation from a living related donor with Crohn's disease. Abstract

  97. A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis. 2004 Jul; 10(4):333-8. View A pilot study of adalimumab in infliximab-allergic patients. Abstract

  98. The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2004 Jul; 10(4):352-6. View The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease. Abstract

  99. TL1A synergizes with IL-12 and IL-18 to enhance IFN-gamma production in human T cells and NK cells. J Immunol. 2004 Jun 01; 172(11):7002-7. View TL1A synergizes with IL-12 and IL-18 to enhance IFN-gamma production in human T cells and NK cells. Abstract

  100. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol. 2004 Apr; 2(4):309-13. View High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Abstract

  101. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology. 2004 Feb; 126(2):414-24. View Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Abstract

  102. Initial experience with wireless capsule enteroscopy in the diagnosis and management of inflammatory bowel disease. Clin Gastroenterol Hepatol. 2004 Jan; 2(1):31-40. View Initial experience with wireless capsule enteroscopy in the diagnosis and management of inflammatory bowel disease. Abstract

  103. Chemokines in inflammatory bowel disease. Curr Allergy Asthma Rep. 2004 Jan; 4(1):83-9. View Chemokines in inflammatory bowel disease. Abstract

  104. Infliximab in the treatment of medically refractory indeterminate colitis. Aliment Pharmacol Ther. 2003 Oct 01; 18(7):741-7. View Infliximab in the treatment of medically refractory indeterminate colitis. Abstract

  105. CC chemokine receptor 9 expression defines a subset of peripheral blood lymphocytes with mucosal T cell phenotype and Th1 or T-regulatory 1 cytokine profile. J Immunol. 2003 Jul 01; 171(1):159-65. View CC chemokine receptor 9 expression defines a subset of peripheral blood lymphocytes with mucosal T cell phenotype and Th1 or T-regulatory 1 cytokine profile. Abstract

  106. Optimizing the therapeutic potential of azathioprine/6-mercaptopurine in the treatment of inflammatory bowel disease. J Clin Gastroenterol. 2003 May-Jun; 36(5):379-81. View Optimizing the therapeutic potential of azathioprine/6-mercaptopurine in the treatment of inflammatory bowel disease. Abstract

  107. Anti-CD2O chimeric monoclonal antibody (rituximab) treatment of immune-mediated thrombocytopenia associated with Crohn's disease. Gastroenterology. 2003 Feb; 124(2):583. View Anti-CD2O chimeric monoclonal antibody (rituximab) treatment of immune-mediated thrombocytopenia associated with Crohn's disease. Abstract

  108. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology. 2002 Sep; 123(3):679-88. View Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Abstract

  109. Diagnosis and misdiagnosis of inflammatory bowel disease. Gastrointest Endosc Clin N Am. 2002 Jul; 12(3):433-49. View Diagnosis and misdiagnosis of inflammatory bowel disease. Abstract

  110. CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease. Gastroenterology. 2001 Aug; 121(2):246-54. View CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease. Abstract

  111. Outcome of cytomegalovirus infections in patients with inflammatory bowel disease. Am J Gastroenterol. 2001 Jul; 96(7):2137-42. View Outcome of cytomegalovirus infections in patients with inflammatory bowel disease. Abstract

  112. The role of thymus-expressed chemokine and its receptor CCR9 on lymphocytes in the regional specialization of the mucosal immune system. J Immunol. 2000 Nov 01; 165(9):5069-76. View The role of thymus-expressed chemokine and its receptor CCR9 on lymphocytes in the regional specialization of the mucosal immune system. Abstract

  113. The role of chemokines and chemokine receptors in mucosal inflammation. Inflamm Bowel Dis. 2000 Nov; 6(4):303-13. View The role of chemokines and chemokine receptors in mucosal inflammation. Abstract

  114. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology. 2000 Oct; 119(4):1148-57. View Tumor necrosis factor: biology and therapeutic inhibitors. Abstract

  115. Late-gestation tracheal occlusion in the fetal lamb causes rapid lung growth with type II cell preservation. J Surg Res. 2000 Jul; 92(1):64-70. View Late-gestation tracheal occlusion in the fetal lamb causes rapid lung growth with type II cell preservation. Abstract

  116. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med. 2000; 51:289-98. View Role of cytokines in the pathogenesis of inflammatory bowel disease. Abstract

  117. Serologic testing in inflammatory bowel disease: its value in indeterminate colitis. Curr Gastroenterol Rep. 1999 Dec; 1(6):482-5. View Serologic testing in inflammatory bowel disease: its value in indeterminate colitis. Abstract

  118. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology. 1999 Dec; 117(6):1278-87. View An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Abstract

  119. Recurrent bleeding from a duodenal plasmacytoma treated successfully with embolization of the gastroduodenal artery. Am J Gastroenterol. 1999 Jun; 94(6):1691-2. View Recurrent bleeding from a duodenal plasmacytoma treated successfully with embolization of the gastroduodenal artery. Abstract

  120. Current theories on the causes of inflammatory bowel disease. Gastroenterol Clin North Am. 1999 Jun; 28(2):283-96. View Current theories on the causes of inflammatory bowel disease. Abstract

  121. The role of apoptosis in normal and accelerated lung development in fetal rabbits. J Pediatr Surg. 1999 May; 34(5):863-70; discussion 870-1. View The role of apoptosis in normal and accelerated lung development in fetal rabbits. Abstract

  122. The changing presentation of pyloric stenosis. Am J Emerg Med. 1999 Jan; 17(1):67-9. View The changing presentation of pyloric stenosis. Abstract

  123. Predictive value of monitoring parameters in fetal surgery. J Pediatr Surg. 1998 Aug; 33(8):1297-301. View Predictive value of monitoring parameters in fetal surgery. Abstract

  124. Temporary tracheal occlusion causes catch-up lung maturation in a fetal model of diaphragmatic hernia. J Pediatr Surg. 1998 Jul; 33(7):1030-7. View Temporary tracheal occlusion causes catch-up lung maturation in a fetal model of diaphragmatic hernia. Abstract

  125. Single-port tracheoscopic surgery in the fetal lamb. J Pediatr Surg. 1998 Jun; 33(6):918-20. View Single-port tracheoscopic surgery in the fetal lamb. Abstract

  126. Stenotrophomonas maltophilia meningitis. Report of two cases and review of the literature. J Neurosurg. 1997 Jul; 87(1):106-8. View Stenotrophomonas maltophilia meningitis. Report of two cases and review of the literature. Abstract

  127. Fetal lung growth after tracheal ligation is not solely a pressure phenomenon. J Pediatr Surg. 1997 Feb; 32(2):347-51. View Fetal lung growth after tracheal ligation is not solely a pressure phenomenon. Abstract

  128. Patterns of pulmonary metastasis from uterine cancer. Oncology. 1996 Sep-Oct; 53(5):360-3. View Patterns of pulmonary metastasis from uterine cancer. Abstract

  129. Natural history of patients with pulmonary metastases from uterine cancer. Cancer. 1996 Aug 01; 78(3):441-7. View Natural history of patients with pulmonary metastases from uterine cancer. Abstract

  130. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am J Med. 1996 Aug; 101(2):170-6. View Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Abstract

  131. Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicenter study of 91 episodes. Clin Infect Dis. 1996 Mar; 22(3):508-12. View Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicenter study of 91 episodes. Abstract

  132. Stenotrophomonas (Xanthomonas) maltophilia urinary tract infection. A disease that is usually severe and complicated. Arch Intern Med. 1996 Feb 26; 156(4):433-5. View Stenotrophomonas (Xanthomonas) maltophilia urinary tract infection. A disease that is usually severe and complicated. Abstract

  133. Septic prepatellar bursitis caused by Stenotrophomonas (Xanthomonas) maltophilia. Clin Infect Dis. 1996 Feb; 22(2):388-9. View Septic prepatellar bursitis caused by Stenotrophomonas (Xanthomonas) maltophilia. Abstract

  134. Stenotrophomonas maltophilia: an unusual cause of biliary sepsis. Clin Infect Dis. 1995 Oct; 21(4):1032-4. View Stenotrophomonas maltophilia: an unusual cause of biliary sepsis. Abstract

Department of Surgery | Education

Undergraduate School

Massachusetts Institute of Technology

Boston, MA

Medical School

State University of New York

Stony Brook, MA

Residency

Beth Israel Deaconess Medical Center

Boston, MA

Fellowship

Boston Children's Hospital

Boston, MA

Department of Surgery | Publications

Department of Surgery | Education

Undergraduate School

Rice University

2007, Houston, TX

Medical School

Harvard Medical School

2011, Boston, MA

Internship

Baylor College of Medicine

2012, Houston, TX

Graduate School

University of Texas School of Public Health

2016, Houston, TX

Residency

Baylor College of Medicine

2018, Houston, TX

Fellowship

Boston Children's Hospital

2020, Boston, MA

Department of Surgery | Publications

Department of Surgery | Education

Medical School

Harvard Medical School

1976, Boston, MA

Internship

Massachusetts General Hospital

1977, Boston, MA

Residency

Massachusetts General Hospital

1986, Boston, MA

Fellowship

Boston Children's Hospital

1988, Boston, MA

Department of Surgery | Publications

Department of Surgery | Education

Undergraduate School

Yale University

2007, New Haven, CT

Medical School

Harvard Medical School

2011, Boston, MA

Internship

Brigham and Women's Hospital and Massachusetts General Hospital

2012, Boston, MA

Residency

Brigham and Women's Hospital and Massachusetts General Hospital

2015, Boston, MA

Fellowship

Brigham and Women's Hospital and Massachusetts General Hospital

2019, Boston, MA

Department of Surgery | Publications

Department of Surgery | Education

Medical School

University of Sao Paulo

1985, Brazil

Internship

Hospital of Clinics of the University of Sao Paulo Medical School

1986, San Paulo, Brazil

Residency

Hospital of Clinics / Children's Hospital of the University of Sao Paulo Medical School

1991, San Paulo, Brazil

Fellowship

Boston Children's Hospital

1997, Boston, MA

Fellowship

Boston Children's Hospital

2000, Boston, MA

Department of Surgery | Publications

Department of Surgery | Education

Undergraduate School

Duke University

2006, Durham, NC

Medical School

University of Florida College of Medicine

2010, Gainesville, FL

Internship

University of Michigan

2011, Ann Arbor, MI

Residency

University of Michigan

2017, Ann Arbor, MI

Fellowship

Boston Children's Hospital

2019, Boston, MA

Department of Surgery | Publications

Talk to Lesley

If this is a medical emergency, please dial 9-1-1. This application should not be used in an emergency. This chat is being transmitted via a secure connection.

Hi! My name is Lesley. I am a virtual agent programmed to help you. If you would like to speak to a live agent, please call 617-355-6000.

I am unable to answer specific questions regarding your child's case, including appointments and conditions/diagnosis. Please contact your physician's office.

Quick links:

- MyChildrens Portal
- Global Services
- Find a Doctor
- Find a Location
- Programs and Services